0_5915 The SPES-ISOLPHARM project at INFN-LNL aims to provide unconventional carrier-free radionuclides for medical applications exploiting the Isotope Separation On-Line (ISOL) technique. Recently, Ag-111 has become of great interest since its beta decay is suitable for Targeted Radionuclide Therapy (TRT) and the following gamma emission could be traced in a theranostic treatment. In the ISOL technique, a crucial role is played by ion sources, since they permit the extraction of the produced radionuclides in the form of radioactive ion beams. Several types of ion sources are currently under development and, among these, the most selective is the Resonant Ionization Laser Ion Source (RILIS). The latest RILIS experiments were focused on the study of the selective photo-ionization of the stable isotopes of silver, Ag-107 and Ag-109. The experimental campaign consisted in two studies making use of silver plasmas produced in a Hollow Cathode Lamp (HCL) and in an ablation plume. In the framework of this medical application, the experiments ISOLPHARM_EIRA (2020-2022) and ADMIRAL (2023-2025) were structured with the purpose of investigating radiopharmaceutical candidates labeled with Ag-111, their therapeutic effects on cells and their possible use in diagnosis.